Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma-Reference-Cited by-同舟云学术

Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma

Published:2022-06-14 Issue:10 Volume:63 Page:2403-2412
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Ho Matthew¹^ORCID,Moscvin Maria²,Low Soon Khai³,Evans Benjamin²,Close Sara⁴,Schlossman Robert⁴,Laubach Jacob⁴,Prada Claudia Paba⁴,Glotzbecker Brett⁵,Richardson Paul G.⁴,Bianchi Giada²

Affiliation:

1. Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA

2. Amyloidosis program, Division of Hematology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

3. Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA

4. LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

5. Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA

Funder

Demarest Lloyd Jr Foundation and the Appleby Cardiac Amyloidosis Fund

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2084729

Reference32 articles.

1. How I treat the young patient with multiple myeloma

2. The role of high‐dose melphalan with autologous stem‐cell transplant in multiple myeloma: is it time for a paradigm shift?